Boston Scientific (NYSE:BSX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, July 24th. Analysts expect the company to announce earnings of $0.58 per share...
Boston Scientific Corporation has obtained CE Mark on the Vercise Neural Navigator 5 Software with STIMVIEW XT technology, which when used as part of the Vercise Genus Deep Brain Stimulation (DBS) Systems, can...
The FDA announced today that it has designated a Boston Scientific recall of its Obsidio conformable embolic as Class I, its most serious level of recall.
The Obsidio embolic is a premixed embolic agent that is delivered in a minimally...
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary...
